About alx oncology holdings inc - ALXO
ALX Oncology Holdings, Inc. is a clinical-stage biotechnology company, which engages in the research and development of therapies for cancer patients. Its objective is to provide clinical therapies for the treatment of myelodysplastic syndromes, acute myeloid leukemia, and a range of solid tumor indications. The company was founded by Corey Goodman, Jaume Pons, and K. Christopher Garcia in March 2015 and is headquartered in South San Francisco, CA.
ALXO At a Glance
ALX Oncology Holdings, Inc.
323 Allerton Avenue
South San Francisco, California 94080
| Phone | 1-650-466-7125 | Revenue | 0.00 | |
| Industry | Biotechnology | Net Income | -101,695,000.00 | |
| Sector | Health Technology | Employees | 43 | |
| Fiscal Year-end | 12 / 2026 | |||
| View SEC Filings |
ALXO Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | N/A |
| Price to Book Ratio | 2.366 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -0.306 |
| Enterprise Value to Sales | N/A |
| Total Debt to Enterprise Value | 0.482 |
ALXO Efficiency
| Revenue/Employee | N/A |
| Income Per Employee | -2,365,000.00 |
| Receivables Turnover | N/A |
| Total Asset Turnover | N/A |
ALXO Liquidity
| Current Ratio | 2.066 |
| Quick Ratio | 2.066 |
| Cash Ratio | 1.824 |
ALXO Profitability
| Gross Margin | N/A |
| Operating Margin | N/A |
| Pretax Margin | N/A |
| Net Margin | N/A |
| Return on Assets | -98.341 |
| Return on Equity | -145.696 |
| Return on Total Capital | -249.552 |
| Return on Invested Capital | -125.61 |
ALXO Capital Structure
| Total Debt to Total Equity | 56.849 |
| Total Debt to Total Capital | 36.245 |
| Total Debt to Total Assets | 25.014 |
| Long-Term Debt to Equity | 29.606 |
| Long-Term Debt to Total Capital | 18.876 |